Literature DB >> 3931929

Mesna does not reduce cisplatin induced nephrotoxicity in the rat.

B C Millar, Z H Siddik, J L Millar, S Jinks.   

Abstract

Although mesna afforded protection against the cytotoxicity of cisplatin in Chinese hamster cells, line V-79-753B, in vitro, there was no evidence for protection against nephrotoxicity when this drug combination was examined in the rat. It seems likely that cisplatin-induced nephrotoxicity is mediated by intracellular events in kidney cells which cannot be inhibited by mesna possibly due to its presence within cells in vivo as the stable and unreactive disulphide. On the basis of these data it is unlikely that combinations of mesna and cisplatin will be of therapeutic benefit in man.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3931929     DOI: 10.1007/bf00263907

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  16 in total

1.  Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention. 2. Comparative study on the uroprotective efficacy of thiols and other sulfur compounds.

Authors:  N Brock; J Pohl; J Stekar
Journal:  Eur J Cancer Clin Oncol       Date:  1981-11

2.  Prophylaxis of haemorrhagic cystitis due to cyclophosphamide-conditioning for bone marrow transplantation.

Authors:  H Link; V Neef; D Niethammer; K Wilms
Journal:  Blut       Date:  1981-11

3.  Inhibition of cis-platinum nephrotoxicity by diethyldithiocarbamate rescue in a rat model.

Authors:  R F Borch; M E Pleasants
Journal:  Proc Natl Acad Sci U S A       Date:  1979-12       Impact factor: 11.205

4.  Rapid determination of urea nitrogen in serum or plasma without deproteinization.

Authors:  C L Crocker
Journal:  Am J Med Technol       Date:  1967 Sep-Oct

5.  Effect of sodium thiosulfate on cis-dichlorodiammineplatinum(II) toxicity and antitumor activity in L1210 leukemia.

Authors:  S B Howell; R Taetle
Journal:  Cancer Treat Rep       Date:  1980 Apr-May

6.  Efficacy of ifosfamide in refractory malignant diseases and uroprotection by mesna: results of a clinical phase II-study with 151 patients.

Authors:  M E Scheulen; N Niederle; K Bremer; J Schütte; S Seeber
Journal:  Cancer Treat Rev       Date:  1983-09       Impact factor: 12.111

7.  Intraperitoneal cis-diamminedichloroplatinum with systemic thiosulfate protection.

Authors:  S B Howell; C E Pfeifle; W E Wung; R A Olshen
Journal:  Cancer Res       Date:  1983-03       Impact factor: 12.701

8.  Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention--III. Profile of action of sodium 2-mercaptoethane sulfonate (mesna).

Authors:  N Brock; J Pohl; J Stekar; W Scheef
Journal:  Eur J Cancer Clin Oncol       Date:  1982-12

9.  Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer.

Authors:  L H Einhorn; J Donohue
Journal:  Ann Intern Med       Date:  1977-09       Impact factor: 25.391

10.  Pharmacokinetics and metabolism of sodium 2-mercaptoethanesulfonate in the rat.

Authors:  K Ormstad; S Orrenius; T Låstbom; N Uehara; J Pohl; J Stekar; N Brock
Journal:  Cancer Res       Date:  1983-01       Impact factor: 12.701

View more
  3 in total

1.  A density functional reactivity theory (DFRT) based approach to understand the interaction of cisplatin analogues with protecting agents.

Authors:  Amrit Sarmah; Ram Kinkar Roy
Journal:  J Comput Aided Mol Des       Date:  2014-09-03       Impact factor: 3.686

2.  Effects of fosfomycin, mesna, and sodium thiosulfate on the toxicity and antitumor activity of cisplatin.

Authors:  T Wagner; B Kreft; G Bohlmann; G Schwieder
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

Review 3.  WR2721 as a modulator of cisplatin- and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach.

Authors:  M Treskes; W J van der Vijgh
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.